SK Plasma Core Moves to Expand Access to IVIG Treatment in Indonesia ... Strengthening the Plasma-Derived Medicines Ecosystem
- Input
- 2026-11-16 17:32:25
- Updated
- 2026-11-16 17:32:25

[Jakarta, Indonesia—Aulia Maulida Hamdani, correspondent] SK Plasma Core’s Indonesian entity has begun efforts to strengthen cooperation among the government, medical community, patient groups and pharmaceutical industry to improve Indonesian patients’ access to intravenous immunoglobulin (IVIG) treatment.
According to local media reports on the 16th, SK Plasma Core Indonesia adopted the “Joint Declaration to Improve IVIG Access in Indonesia” at the 2026 Health Innovation Festival (HAI Fest), highlighting the importance of early diagnosis, equitable supply of medicines and building a plasma-derived medicinal products (PDMP) ecosystem.
IVIG is a plasma-derived medicine used to treat patients with certain conditions, including primary immunodeficiency and Kawasaki disease. A discussion at the event addressed the challenges patients face in recognizing symptoms, obtaining a diagnosis and securing treatment, and emphasized the need to raise awareness among healthcare professionals and the public to promote early diagnosis.
The joint declaration included a commitment to strengthen cooperation among patient groups, the medical community, the government and the pharmaceutical industry, and to step up efforts to ensure a timely and stable supply of IVIG. The participants also agreed to develop Indonesia’s plasma-derived medicines ecosystem to improve the stability of medicine supplies.
Noh Hyeon-ho, head of SK Plasma Core’s Indonesian entity, said, “For early diagnosis to benefit patients who need IVIG, the medicine must be available when treatment is actually needed.” He added, “Building local production capacity on the foundation of a stable plasma supply chain and cooperation among stakeholders could, over the long term, improve the stability of medicine supplies and patients’ access to treatment.”
Indonesia currently relies on imports to meet demand for plasma-derived medicines, leaving patients vulnerable to disruptions in global supply chains. In response, SK Plasma is working with the Indonesia Investment Authority (INA) to develop a plasma fractionation facility in Karawang, West Java Province, and continues to collaborate with local partners on plasma collection. The plan is to strengthen the stability of medicine supplies over the long term by building local production capacity.
[email protected] Aulia Maulida Hamdani, Correspondent Reporter